TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8021329
Drug: Tapered-dose transdermal
Normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered-dose transdermal nicotine (21 or 22 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks)
Study: 8021329
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg TID for 7 days, then 10 mg TID for 21 days)
Study: 2563951
Drug: Coated mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coated mesalazine (Mesasal) 1.5 g daily
Study: 2563951
Drug: Sulphasalazine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine 3.0 g daily
Study: 31492505
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg once daily) plus a P2Y12 inhibitor for 12 months
Study: 31492505
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) in combination with a P2Y12 inhibitor and aspirin (100 mg once daily, for 1-12 months)
Study: 24787143
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg/d
Study: 24787143
Drug: Vortioxetine 20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 20 mg/d
Study: 20414864
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of recent-onset rectal bleeding
Study: 16055161
Drug: A‐linked proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐linked proanthocyanidins from cranberry juice cocktail at 60 microg/ml
Study: 16055161
Drug: B‐type proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐type proanthocyanidins from grape at 1200 microg/ml
Study: 11736673
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg kg(‐1) with fentanyl 100 microg)
Study: 9225827
Drug: Ethanol (0.52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.52 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Study: 9225827
Drug: Ethanol (0.69
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.69 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Study: 9225827
Drug: Ethanol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (higher dose)
Study: 2585237
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered immune globulin (IVIG)
Study: 20023357
Drug: Hyaluronan (Hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (Hylan G‐F 20)
Study: 16911176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tobacco and drug education curriculum)
Study: 16209203
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (antibiotic, indomethacin, alpha1 receptor blocker and Chinese traditional medicine)
Study: 16209203
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication plus psychologic treatment
Study: 9644786
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 20 mg/40 ml
Study: 9644786
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 50 mg/100 ml
Study: 3366160
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (5 mg i.v.)
Study: 31487739
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (50 mg, i.v.)
Study: 31487739
Drug: Intralipid (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (0.1 mL/kg, i.v.)
Study: 28667201
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) in conjunction with treatment as usual (mostly pharmacotherapy and clinical monitoring)
Study: 3552360
Drug: Fluradoline, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluradoline, 300 mg
Study: 3552360
Drug: Fluradoline, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluradoline, 150 mg
Study: 24929459
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of phylloquinone (vitamin K1) in SP6
Study: 22587416
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus concurrent chemoradiotherapy (69 patients)
Study: 9928561
Drug: Primary endocrine
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endocrine therapy
Study: 7706955
Drug: Phasic exercises
Normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phasic exercises and chiropractic therapy (Group 2, n = 15)
Study: 7706955
Drug: Standard exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercises (stretching/isometric/isokinetic) and chiropractic therapy (Group 1, n = 15)
Study: 2533024
Drug: Flunoxaprofen 400
Normalized name: flunoxaprofen
DrugBank: Flunoxaprofen (DB13317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunoxaprofen 400 mg/day p.o. for 30 days
Study: 2533024
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg/day p.o. for 30 days
Study: 31811645
Drug: DPBM with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPBM with adjunctive use of EMD (test group, n = 20)
Study: 25400471
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate tablets (NaP, CLICOLONTM)
Study: 25400471
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol solution (PEG)
Study: 18646498
Drug: Meloxicam pre‐emptively
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam pre‐emptively administered
Study: 6610580
Drug: Fenbufen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (600 mg)
Study: 27695824
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg continuous infusion for 5 days, followed by tapering until day 11)
Study: 23726851
Drug: Pramipexole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (1.5 mg a day)
Study: 21849596
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg docosahexaenoic acid (DHA) + 150 mg eicosapentaenoic acid (fish oil)
Study: 21849596
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg 5-methyltetrahydrofolate (5-MTHF)
Study: 9762492
Drug: Direct with
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct with indirect therapy
Study: 2108889
Drug: 3.75 or
Normalized name: Zileze 3.75 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 or 7.5 mg leuprorelin acetate depot given subcutaneously once every 4 weeks
Study: 7001332
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy (25 mg daily by mouth for the first six weeks of life)
Study: 26059696
Drug: Chemotherapy compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy compliance reporting
Study: 23934621
Drug: GSK1521498 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 20 mg
Study: 23934621
Drug: GSK1521498 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 20 mg + Ethanol 0.5 g/kg body weight
Study: 21367761
Drug: Chondroitin sulphate
Normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulphate (CS) 800 mg once daily for 6 months
Study: 15126148
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sildenafil (Viagra)
Study: 11217092
Drug: Ninjin-to (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninjin-to (6.0 g)
Study: 9448590
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids and oral cyclophosphamide (CY; 2 mg/kg/day) for 1 yr (group A)
Study: 9448590
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids and monthly i.v. CY pulses (0.6 g/m2) for 1 yr (group B)
Study: 384188
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus chemotherapy
Study: 25758370
Drug: Zn +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn + Se (ZS; 30 mg Zn as zinc‐gluconate and 200 μg Se as high‐selenium yeast)
Study: 23628045
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug group treated with corticosteroid and anti-helicobacter pylori treatment
Study: 23628045
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug group treated only with corticosteroid
Study: 18771564
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement of 800 IU vitamin D from 27 weeks until delivery
Study: 18771564
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200,000 IU vitamin D
Study: 15054378
Drug: Pentoxifylline (Ptx)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Ptx) 400 mg 3 times a day orally (total 1200 mg)
Study: 9597571
Drug: Intermediate-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cyclophosphamide (2 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (ID-Cy)
Study: 9597571
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (4 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (HD-Cy)
Study: 9597571
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-Cy)
Study: 9597571
Drug: Intermediate-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cyclophosphamide (ID-Cy)
Study: 8062773
Drug: Plasma derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma derived HB vaccine
Study: 8062773
Drug: Recombinant HB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HB vaccine
Study: 2890903
Drug: GLP-1 7-36
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 7-36 infusion
Study: 29742960
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice-daily
Study: 16875644
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen/medroxyprogesterone acetate [0.625/2.5 mg]
Study: 1510005
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of insulin (0.1 U/kg body weight 4 times a day for 7 days)
Study: 1510005
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of insulin
Study: 1510005
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of insulin (once, n = 6)
Study: 29610982
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (Gluma and Duraphat)
Study: 27310945
Drug: Normal temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal temperature solution
Study: 17472001
Drug: Cernilton for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton for 3 months + antibacterial treatment for 8 months (group IIa)
Study: 17472001
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic treatment for 2 months maximally (group IIb)
Study: 12086555
Drug: Anakinra (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (human recombinant interleukin‐1 receptor antagonist)
Study: 12086555
Drug: Anakinra (monotherapy)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra (monotherapy)
Study: 12086555
Drug: Anakinra plus
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra plus methotrexate (combination therapy)
Study: 7899379
Drug: Aspirin 900
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 900 mg-metoclopramide 10 mg effervescent association (AAM)
Study: 28751548
Drug: Pioglitazone 15-30
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15-30 mg
Study: 19341122
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) with N-acetylcysteine (NAC)
Study: 19341122
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) without N-acetylcysteine (NAC)
Study: 15490811
Drug: letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole 2.5 mg
Study: 15490811
Drug: anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: anastrozole 1 mg
Study: 11557681
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (1 mg 17beta‐estradiol combined with 0.5 mg norethisterone acetate)
Study: 9786808
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for 10 weeks
Study: 9786808
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific antidepressant treatment)
Study: 7973171
Drug: Incentives, enablers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentives, enablers, medication monitors, and chemotherapeutic regimens allowing direct administration of medication combined with effective patient-physician relationship
Study: 7973171
Drug: Traditional health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional health education and medication labeling methods
Study: 28371900
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content (VLNC; 2.4 mg/g nicotine or less) cigarettes
Study: 28371900
Drug: Normal nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal nicotine content (NNC; 15.8 mg/g) cigarettes
Study: 26601156
Drug: AAV9-IGHMBP2 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAV9-IGHMBP2 administration via systemic injection
Study: 26601156
Drug: AAV9-IGHMBP2 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAV9-IGHMBP2 administration in human SMARD1-induced pluripotent stem cell-derived motor neurons
Study: 23967638
Drug: Botox group
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox group (local injection of botox type A)
Study: 19596010
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 mg/d for weight <35 kg; 20 mg/d for weight >35 kg)
Study: 16705580
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic Lactobacillus casei subspecies rhamnosus (6 x 10^9 cfu/day) added to human milk
Study: 29343509
Drug: Tregalizumab 25
Normalized name: Tregalizumab
DrugBank: Tregalizumab (DB13073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregalizumab 25 mg
Study: 29343509
Drug: Tregalizumab 100
Normalized name: Tregalizumab
DrugBank: Tregalizumab (DB13073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregalizumab 100 mg
Study: 29343509
Drug: Tregalizumab 200
Normalized name: Tregalizumab
DrugBank: Tregalizumab (DB13073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregalizumab 200 mg
Study: 26811968
Drug: CHoBI7 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHoBI7 intervention (hand washing with soap and water treatment)
Study: 24980662
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 200,000 IU for 2 months followed by 100,000 IU monthly for 18 months
Study: 17636181
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment course in Tunisia
Study: 12443741
Drug: Lignocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (5 ml of 1% lignocaine)
Study: 12443741
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo (5 ml)
Study: 10502216
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus accelerated tissue plasminogen activator (TPA)
Study: 7206052
Drug: 5-fluorouracil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (600 mg per M², administered intravenously weekly)
Study: 29174928
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g IN
Study: 29174928
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g IN
Study: 29174928
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g IN
Study: 21557777
Drug: Intralesional cryosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional cryosurgery with pain-control protocol (oral pain-relief tablets Dipyrone and translesional local anaesthesia with Bupivacaine hydrochloride 0.5%)
Study: 17688080
Drug: Monodoks 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monodoks 100 mg capsule (test preparation)
Study: 17688080
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule of the originator product (reference preparation)
Study: 12443524
Drug: Combined physiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physiotherapy program (manual therapy, exercise, education)
Study: 7852490
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) therapy (0.04 +/- 0.01 IU/kg daily)
Study: 2045853
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific antibody mentioned)
Study: 6988941
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid preparation (Link)
Study: 30939085
Drug: Minimal-effect treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-effect treatment
Study: 21544313
Drug: edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 30 mg
Study: 21544313
Drug: edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 60 mg
Study: 21544313
Drug: edoxaban 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 120 mg
Study: 21544313
Drug: fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: fondaparinux 2.5 mg
Study: 17956811
Drug: Auditory discrimination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory discrimination therapy (ADT)
Study: 9162303
Drug: DFMO 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.125 g/day
Study: 9162303
Drug: DFMO 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.25 g/day
Study: 9162303
Drug: DFMO 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.5 g/day
Study: 9162303
Drug: DFMO 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 1.0 g/day
Study: 9162303
Drug: DFMO doses
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO doses of > or = 1 g/day
Study: 24843313
Drug: Oxycodone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (1 mg) and ketorolac (1.5 mg)
Study: 24843313
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 mcg) and ketorolac (1.5 mg)
Study: 24843313
Drug: Oxycodone and
Normalized name: oxycodone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone and Fentanyl
Study: 16533870
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg before CS/US pairing
Study: 16533870
Drug: Flumazenil 1
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1 mg before conditioning
Study: 16533870
Drug: Flumazenil 1
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1 mg after conditioning
Study: 15448917
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for BPD
Study: 11876690
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha-2b (10 MU daily for 10 days, then 5 MU daily for 74 days, then 5 MU three times weekly for 24 weeks)
Study: 11876690
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha-2b with ribavirin (1000-1200 mg/day starting at day 11)
Study: 11876690
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha-2b
Study: 10215775
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (200 mg twice daily for 1 week per month for 3 months)